Association of two key variants mapping to the MTHFR gene (C677T (rs1801133) and A1298C (rs1801131)) with response to methotrexate (MTX) remains controversial. We investigated these and other markers spanning the gene as predictors of MTX efficacy and adverse events in a UK rheumatoid arthritis (RA) patient cohort and performed a meta-analysis of the two key variants using all published data. The tagging single nucleotide polymorphisms (SNPs) were genotyped in 309 patients with well-defined outcomes to MTX treatment and 17 studies were included in the metaanalysis. No association of the SNPs tested was detected with MTX efficacy or toxicity in our UK cohort. After combining our data with previous studies by meta-analysis, the random effects pooled odds ratios (OR) for both C677T and A1298C showed no association with efficacy or toxicity for either of the SNPs (efficacy: OR ¼ 1.05 (95% confidence interval (CI) 0.83-1.32) and OR ¼ 0.81 (95% CI 0.53-1.24), respectively; toxicity: OR ¼ 1.38 (95% CI 0.90-2.12) and OR ¼ 1.19 (95% CI 0.80-1.78), respectively). The available evidence suggests that the MTHFR C677T and A1298C gene polymorphisms are not reliable predictors of response to MTX treatment in RA patients.
Introduction
The main goals in the management of rheumatoid arthritis (RA) are to control pain, prevent or control joint damage and avoid long-term loss of function. Drug therapy is a key component of the treatment pathway and disease modifying anti rheumatic drugs (DMARDs) have become the mainstay of treatment in order to control symptoms and modify radiographic progression in the long term. There are several DMARDs available; however, since its re-introduction in the early 1980s, methotrexate (MTX) has become the most widely used DMARD in clinical practice and is increasingly recognised as the anchor drug for the treatment of RA. [1] [2] [3] [4] Although combined efficacy and continuation rates with MTX have proven to be better than other DMARDs, there is still considerable inter and intra patient variability. It is estimated that up to one third of patients fail to respond to treatment either due to lack of efficacy or adverse events (AEs) and this variation in response and toxicity limits treatment in some patients. [5] [6] [7] Various factors have been shown to influence treatment response including individual patient factors, disease-specific factors and genetic factors. [8] [9] [10] [11] As there are still no consistently reliable clinical or molecular markers to accurately predict response to MTX therapy, pharmacogenetic markers may offer a strategy to help identify those patients that are more likely to respond to MTX or experience AE. With the accumulating evidence that earlier treatment with DMARD therapy improves long-term outcomes, identification of stable and reliable predictors of MTX response is becoming even more desirable. 12 MTX is an anti-metabolite drug that was first developed as a folic acid analogue and was used initially to treat leukaemia and then later, RA. 13 The actual mechanism of action of low-dose MTX used to treat RA is still not fully understood, but it is thought that the anti-inflammatory elements are more important than its anti-proliferative effects. Methylenetetrahydrofolate reductase (MTHFR) is the best studied gene in the MTX cellular pathway and encodes a protein with several important roles, including the conversion of the prominent circulatory form of folate, 5,10-methylenetetrahydrofolate required for purine and thymidine synthesis, to 5-methyl tetrahydrofolate, which acts as a carbon donor for the re-methylation of homocysteine to methionine by methionone synthase. Hence this enzyme has a key role in the fine balance between DNA synthesis, repair and methylation and single nucleotide polymorphisms (SNPs) in the MTHFR gene may act as useful markers for predicting efficacy and toxicity in RA patients treated with MTX.
The MTHFR gene is located on chromosome 1 (1p36.3) and has 11 exons spanning 22 kb. 14, 15 Several polymorphisms have been identified in this gene, but the most well described are two non-synonymous genetic variants: C677T (rs1801133) and A1298C (rs1801131), both of which have been reported to be associated with altered phenotypes. 16, 17 Previous studies investigating the correlation of MTHFR SNPs with response to MTX in RA have generally focused on the aforementioned SNPs and have yielded conflicting results. For example, Urano et al. 18 reported that the 677T allele was associated with greater toxicity and the 1298C allele with better efficacy. Association of the 677T allele with MTX toxicity (worse clinical outcome) have been confirmed by some [18] [19] [20] [21] [22] but not all studies, [23] [24] [25] [26] [27] [28] [29] [30] [31] there being less confirmatory evidence for an association with efficacy. 31, 32 There is less data investigating the role of the A1298C SNP modulating response to MTX therapy but most studies have reported that the C allele is associated with reduced AE/ increased efficacy 18, 20, 24, 25, 33 or demonstrate no association. 26, 27 The variability in individual study findings may arise due to the fact that each includes a small sample size thereby reducing the power to accurately estimate effect sizes. In order to determine whether SNPs within the gene are actually correlated with efficacy and AE outcomes, we have, first, genotyped these and other polymorphisms within the MTHFR gene in our own patient cohort and, second, undertaken a meta-analysis of all the relevant published studies of MTHFR polymorphisms, incorporating results from our own study. In this meta-analysis a pooled estimate of the risk was obtained and heterogeneity between studies investigated.
Materials and methods

Study subjects and genotyping
We genotyped all SNPs in our own patient cohort, comprising 309 RA patients treated with MTX monotherapy and classified as good responders (n ¼ 147), inefficacy failures (n ¼ 101) (based on clinician judgment, MTX dose and measures of erythrocyte sedimentation rate and C-reactive protein) and AE failures (n ¼ 61) (AE had to be serious and lead to treatment cessation) as described in detail by Hider et al. 34 to determine if they were associated with response. A pair-wise tagging SNP approach was adopted, supplemented with the two commonly investigated MTHFR SNPs from the literature. Marker coverage of the gene was extended to include the 10-kb upstream and downstream flanking region. Tag SNPs for the gene were selected from the CEUP/CEU Hapmap data set (Phase II and III release 27) (http:// www.hapmap.org) and this downloaded SNP data was then filtered through the Haploview software (http://www.broad. mit.edu/haploview/) and pair-wise tagging SNPs (r 2 cutoff 40.8 and minor allele frequency 45%) were selected for genotyping. 35 SNP genotyping was performed using the Sequenom iPLEX s MASS ARRAY platform according to the manufacturer's instructions (Sequenom, San Diego, CA, USA; http://www.sequenom.com). Quality control procedures before analysis were used such that 80% sample and SNP genotyping success rate was required and any sample and SNP that fell outside of this threshold were removed.
Published study identification and selection for meta-analysis All studies investigating the relationship between MTHFR SNPs and treatment response in RA published before September 2010 were identified by computer-based searches of the PubMed database and OVID, using the following criterion 'MTHFR or methylenetetrahydrofolate reductase' and 'A1298C', 'C677T' and 'rheumatoid arthritis (RA)'. The retrieved studies were then read in their entirety to assess the appropriateness for inclusion in the meta-analysis. Only studies in human subject and using validated genotyping methods were included. Case reports, editorials and review articles were excluded and the search was restricted to articles in English.
Eligible studies included those that determined the genotype/allele distribution of the C677T and A1298C polymorphisms in patients with RA being treated with MTX who had responded to treatment (controls/referent group) or not responded to treatment/had experienced AEs (cases). The following data was extracted from each study: first author, year of publication, ethnicity of study population, patient numbers and outcome measures. The frequencies of the alleles and genotypic distributions were extracted or calculated for both outcome groups (non-responders and AEs). The studies included in the final analysis were conducted in different patient populations and used different methods and assessment criteria to classify response and AE; therefore, this was taken into consideration during subsequent analysis when considering between study heterogeneity.
Statistical analysis
In the UK cohort genotyped in the current study, a w 2 -test was used to compare allele and genotype frequencies first between responders and non-responders to MTX and, second, between responders and those experiencing an AE. The threshold for significance was defined at trend Pp0.05 and associations were expressed as trend P values, allelic odds ratios (ORs) and their 95% confidence intervals (CIs).
For the meta-analysis, statistical analysis was performed using STATA v9 software using the metan module (Stata, College Station, TX, USA). Genotype frequencies for the MTHFR C677T and A1298C polymorphisms were determined. We examined the contrast of CC versus (CT þ TT) for the C677T polymorphism and AA versus (AC þ CC) for the A1298C polymorphism. This corresponded to a dominant model, assuming a dominant effect of the minor allele, which was consistent with previous meta-analysis and allowed inclusion of the maximum number of studies. 36, 37 For each study, the point estimate of risk, the OR and corresponding 95% CI of responders versus non-responders/ AEs to MTX were calculated. Then the overall pooled OR and corresponding 95% CI was estimated using MantelHaenszel's method with fixed effect models and where appropriate the DerSimonian and Laird method in the random effects models based on the individual ORs. 38, 39 The random effects model assumes different underlying effects, considering both within-and between-study variation, offering an advantage as it accommodates diversity between studies and provides a more conservative estimate. Finally a visual inspection of Begg's funnel plots and Begg and Egger's asymmetry tests was used to investigate publication bias. 40 Heterogeneity of the studies was assessed on the basis of the Cochrane Q test using a significance level (P-value) of 0.05, below which heterogeneity was considered statistically significant. 41 The heterogeneity was also quantified using the I 2 statistic, which is independent of the number of studies in the meta-analysis. This statistic quantifies the effect of heterogeneity, providing a measure of the degree of inconsistency in the study's results. 42 The I 2 statistic takes values between 0 and 100% and describes the percentage of total variation across studies that is due to heterogeneity rather than chance. A higher I 2 values denotes a greater degree of heterogeneity (0-25% no heterogeneity, 25-50% moderate heterogeneity, 50-75% large heterogeneity, 75-100% extreme heterogeneity). As calculation of heterogeneity across studies is only one of the components to the investigation of variability, it is also sensible to consider diversity in clinical and methodological aspects. To explore this in addition to the main (overall) analysis, which included all available data, subgroup analysis for each ethnic group was performed. Ethnicity was categorised into Caucasian descent (European and American whites) and non-Caucasian descent (East Asian, South American and Jewish). Sensitivity analysis was also performed: outlying studies (defined as studies in which the 95% CI of a single study did not overlap with the 95% CI of the pooled estimate) were identified and excluded and the I 2 estimates for these different sets of studies examined. 43 Finally meta-regression was used to consider subgroup analysis and investigate the causes of heterogeneity considering whether study characteristics such as ethnicity, study design (prospective/retrospective) or outcome definition (efficacy and AE) could explain the variability of results between studies. The regression analysis included the natural logarithm of the OR as the dependent variable and the study co-variants (for example ethnicity) as the explanatory variable. Meta-regression analyses provide the outcome in the form of a regression co-efficient and CIs. The regression co-efficient represents the difference in effect between trials rated on the two levels of categorical variables. It is expected that the covariate explains between study heterogeneity and meta-regression adjusts for these sources of heterogeneity. 44 
Results
MTHFR tagging SNP results from our patient cohort Nine SNPs were selected for testing in the MTHFR gene, this provided 75% coverage of the gene with allele frequencies 45%. Overall we found no significant associations with any of the SNPs, including the C677T SNP and MTX inefficacy (OR 1.31 95% CI 0.87-1.97) or AE (OR 1.05 95% CI 0.64-1.72). Similarly, no association of the A1298C SNP and MTX inefficacy (OR 0.69 95% CI 0.45-1.05) or AE (OR 0.88 95% CI 0.54-1.43) ( Table 1 ).
Meta-analysis: studies included
Data from 27 studies investigating MTHFR SNPs and MTX related efficacy and toxicity in RA patients were initially identified through the database searches [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] and combined with results from our study, leaving 28 studies for review. From these, 11 studies were excluded due to lack of available data, leaving 17 studies including the present study published between 2001 and 2010 meeting the eligibility criteria, which were included in the meta-analysis: [18] [19] [20] [22] [23] [24] [25] [26] [27] [28] 32, 33, 45, 46, 53, 54 For the C677T SNP, 10 studies were included for the efficacy analysis and 13 studies for the toxicity analysis (Table 2 ) and for the A1298C SNP 8 studies were included for the efficacy analysis and 8 studies for the toxicity analysis (Table 3 ). Studies were conducted in different populations: six were conducted in populations of East Asian ethnicity, 18, 20, 22, 23, 26, 27 seven involved European and Jewish populations 19, 24, 25, 32, 33, 46, 53 and three studies were conducted in American populations. 28, 45, 54 All used validated genotyping methods. Overall, including information from our own patient cohort, the analysis included data from 1375 patients for the C677T polymorphism efficacy analysis and 2043 for the toxicity analysis and for the A1298C polymorphism, data from 1140 patients were included in the efficacy analysis and 1239 in the toxicity analysis. Tables 2 and 3 summarise  the results of the individual studies and Table 4 shows the individual study characteristics.
Meta-analysis of MTHFR C677T efficacy and toxicity
Overall results from the fixed effects analysis investigating the association between the MTHFR C677T SNP and response to MTX treatment revealed no association with efficacy: (OR 1.04 95% CI 0.82-1.32), but did reveal a statistically significant association with toxicity: (OR 1.52 95% CI 1.24-1.88), specifically in the non-Caucasian group (OR ¼ 1.93 95% CI 1.47-2.55). There was no heterogeneity between studies in terms of efficacy (I 2 ¼ 0% P ¼ 0.49) but extreme heterogeneity when toxicity was the outcome measured (I 2 ¼ 71.2% Po0.0001). Due to the extreme heterogeneity with the combined toxicity studies, random effects models were tested and did not demonstrate a significant association with toxicity (OR 1.38 95% CI 0.90-2.12) (Figures 1 and 2) .
To further investigate the heterogeneity among the reports of toxicity using a random effects model, first, a sensitivity analysis was undertaken and this identified the study by Kim et al. 22 as an outlier; removing this data from the metaanalysis reduced the heterogeneity (I 2 ¼ 49.8% P ¼ 0.025), although it remained statistically significant and the pooled OR was nonsignificant (1.20 95% CI 0.84-1.72). Next, the studies were divided into two groups based on ethnicity (Caucasian and non-Caucasian) (Figure 2 ). There was reduced heterogeneity detected for the toxicity studies among the five pooled Caucasian studies 19, 24, 28, 53 (I 2 ¼ 51.1% P ¼ 0.08), but the mean effect across studies suggested no association with toxicity (OR ¼ 1.12 95% CI ¼ 0.69-1.82). Significant heterogeneity remained between the eight studies restricted to nonCaucasian populations 18, 20, 22, 23, [25] [26] [27] 54 (I 2 ¼ 74.62% Po0.001) but again, no association with toxicity was detected (OR ¼ 1.56 95% CI ¼ 0.83-2.93).
Meta-regression results did not suggest a significant association between the effect size and the study co-variates tested (data not shown). Following visual inspection of the funnel plots there was no clear evidence to suggest publication bias (data not shown).
Meta-analysis of MTHFR A1298C efficacy and toxicity
Results from the fixed effects analysis investigating the association between MTHFR A1298C SNP and response to MTX treatment revealed no association with either efficacy or toxicity with moderate heterogeneity between studies detected for both efficacy (I 2 ¼ 58.3% P ¼ 0.02) and toxicity (I 2 ¼ 51.9% P ¼ 0.04). For this reason random effect models were used for further analysis. The results for the random effects analysis showed no association with either efficacy (OR ¼ 0.81 95% CI 0.53-1.24) or toxicity (OR 1.19 95% CI 0.80-1.78) (Figures 3 and 4) .
In order to reduce the heterogeneity, the studies were divided into two groups based on ethnicity (Caucasian and non-Caucasian) (Figures 3 and 4) . For efficacy outcomes there was moderate, although not statistically significant heterogeneity detected among the four studies contributing to the analysis in Caucasians 32,33,46 (I 2 ¼ 44.0% P ¼ 0.14) and the mean effect across studies was not statistically significant (OR ¼ 0.99 95% CI 0.64-1.53). Significant heterogeneity remained between the four studies restricted to non-Caucasian populations 18, 20, 26, 27 (I 2 ¼ 60.4% P ¼ 0.05) but again, on average there was no association with efficacy detected (OR ¼ 0.63 95% CI 0.30-1.33) (Figure 3 ). In terms of toxicity outcomes the heterogeneity was moderate, albeit nonsignificant for both Caucasian (I 2 ¼ 43.5% P ¼ 0.13) 32,53 and non-Caucasian (I 2 ¼ 59.2% P ¼ 0.086) 18, 20, 25, 27, 54 populations and the mean effect across studies for both Caucasian (OR ¼ 1.49 95% CI 0.84-2.62) and non-Caucasian (OR ¼ 0.98 95% CI 0.57 -1.70) populations was not statistically significant ( Figure 4) . Meta-regression results did not suggest a significant association between the effect size and the study co-variates tested (data not shown). Following visual inspection of the funnel plots there was no clear evidence to suggest publication bias (data not shown). MTHFR gene polymorphisms and outcome of MTX treatment
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Discussion
We have found no evidence to support association of several MTHFR gene polymorphisms with either efficacy or toxicity of treatment with MTX in a UK cohort of RA patients selected for the presence of well-defined and unequivocal phenotypic responses to MTX therapy. Further, we have added our own data for two key polymorphisms (C677T and A1298C) to other published data to undertake the largest meta-analysis, to date. The available evidence suggests that the MTHFR gene polymorphisms tested cannot be considered as reliable predictors of response to MTX treatment, which in relation to the most commonly reported SNPs in the literature is consistent with two previously published meta-analysis that included a smaller number of studies. 36, 37 Whether the C677T SNP is associated with toxicity remains inconclusive because, using a fixed-effect but not a random effect model, there was evidence of association with toxicity particularly in the non-Caucasian group, but with extreme heterogeneity between studies, this being consistent with results published by Fisher et al. 36 This heterogeneity was reduced, but not eliminated, when the meta-analysis was repeated in subgroups of different ethnicity and after removing studies regarded as outliers. Indeed, using random effects models the point estimate of the OR for the association of the C677T SNP with MTX toxicity in nonCaucasians was greater than that in Caucasians although this did not achieve statistical significance and high heterogeneity remained. Recent studies have suggested that individuals with the 677TT genotype may need to consume more folate to maintain serum folate levels similar to those found in individuals with the 677CC/677CT genotypes. 55 A stronger association in non-Caucasians may be consistent with this as a relatively low-folate intake has been described, for example, in the Japanese population and furthermore, in that population, lower concomitant folate doses are administered with MTX. 56, 57 This may explain why the study by Kim et al. 22 was identified as an outlier study as all patients received a low dose of folate (1 mg) compared with other studies included in the meta-analysis. Additional studies in both Caucasian and non-Caucasian populations will be required to explore this further.
Given that genetic effects in complex traits, such as response to treatment, are modest, large sample sizes are required. Meta-analysis offers the opportunity to reach stronger conclusions by combining evidence reported by different studies, thus increasing power, precision of results and allowing analysis of the consistency of effect across different patient populations. This meta-analysis focused on two SNPs in the MTHFR gene and their role in response to MTX in RA, because first, MTHFR is a key gene in the MTX metabolic pathway and increasingly drug metabolism pathway genes are being implicated in response and toxicity to a number of common treatments. One of the best examples is that polymorphisms within genes involved in the metabolism of vitamin K in (VKORC1) and in cytochrome p450 genes (CYP2C9), both involved in the metabolism of warfarin, are predictive of warfarin response. 58 Second, both SNPs investigated are non-synonymous, causing amino-acid alterations in the protein product. The C677T SNP encodes an alanine to valine substitution, at codon 222, which results in a more thermolabile variant of MTHFR with decreased enzyme activity, increased plasma homocysteine level, particularly in the context of folic acid deficiency, and alterations in folate distribution. 16, 59, 60 It is reported that in people carrying the T allele, enzyme activity is decreased in a dose-response fashion in heterozygotes and homozygotes, resulting in smaller pools of methylenetetrahydrofolate. 61, 62 The A1298C SNP causes a glutamic acid to alanine substitution at codon 429. 17 This change is also thought to be associated with reduced enzyme activity, individuals homozygous for the C allele showing 60% enzyme activity in lymphocytes. 17, 63 Two meta-analyses have been previously published examining the effects of the association between the MTHFR A1298C and C677T polymorphisms and MTX response. These meta-analyses published in 2009 and 2010 included a maximum of eight studies and 1514 patients and found no association with the MTHFR gene polymorphisms and response to MTX. However four more studies have been published since and included in the present meta-analysis. Furthermore, we have investigated these genetic variants directly in our own MTX-treated patient series from patients meeting well-characterised, extreme and defined response criteria. This data has also been included in this metaanalysis substantially increasing the number of patients with genetic information, resulting in an additional 1100 patients (2614 in total) and enhancing power.
The lack of a significant association in this study and meta-analysis may represent a true result, but the possibility of a false-negative finding requires consideration because, although we tried to maximise gene coverage, there was still a proportion of the gene that was not captured using a tagging SNP approach; furthermore, we cannot exclude that rare variants and less common SNPs (minor allele frequency 40.01) may have a role in influencing response to MTX, but we did not have enough power to investigate them. In terms of the meta-analysis, first, the results of the present report are based on a relatively small number of studies and participants; although this represents the largest number studied to date, not all studies identified by the initial literature search could be included in the meta-analysis due to lack of available data, which may have resulted in some bias. However, a robust systematic review was conducted to reduce possible selection bias and formal testing revealed no evidence of publication bias. Second, not all studies discriminated between heterozygote and homozygote genotypes; hence the meta-analysis was performed using a dominant model, combining all patients that deviated from the wild type; although this allowed the inclusion of more studies, the inability to undertake an analysis based on genotype or allele frequency may have limited the statistical power. Third, heterogeneity was apparent between the studies, particularly those conducted in non-Caucasian populations. This may have arisen because of the use of different definitions of response and toxicity or because studies were conducted with different study designs and settings (retrospective/prospective, inpatient/outpatient) in several different countries across different racial groups. The latter is particularly important as regional and geographical differences in environmental modifiers, such as folate status that may be affected by local diets, may be present. Causes of heterogeneity were considered and meta-regression analysis did not suggest a significant association between the effect size and the study co-variates tested (ethnicity, study design, outcome definition). Folic acid supplementation and dose of MTX were not formally tested, as this broadly correlated with ethnicity (non-Caucasians generally had lower doses of MTX). Finally, whether MTX was used as monotherapy or in combination with other DMARDs could have confounded the results. In order to explore that, we repeated the meta-analysis restricting the studies included to those where patients were treated with MTX monotherapy. This left a small number of studies for each outcome (n ¼ 2 and n ¼ 3 see Table 4 ), although the point estimates were very similar to the overall results of the meta-analysis. There could, however, be other environmental modifiers and patient-related factors (co-morbidities, disease duration) that differ between studies but, due to lack of information, we were unable to address these. One of the main challenges in undertaking the meta-analysis was the inconsistency in patient outcome definitions and measurements. Ideally, definitions of outcome should be standardized between studies; for example, the efficacy outcomes in the included studies ranged from very subjective measures of response using visual analogue scales, arbitrary cutoffs with MTX dose (for example, o6 mg ¼ responder in many of the Japanese studies), or the DAS response score. What the best measure of efficacy is remains uncertain, with some supporting the DAS 28 because it is used clinically to inform treatment decisions whereas others suggest a more objective biological marker of response such as the erythrocyte sedimentation rate or C-reactive protein should be adopted. In order to effectively assess the combined effects of genes across studies using meta-analysis techniques, patients in all studies would be well characterised, have been uniformly treated and systematically evaluated for toxicities and efficacy using well-defined clinically relevant outcome measures, including prospectively evaluating gene-environment interactions.
Despite these limitations, the overall results of the analysis showed no association of the MTHFR genetic polymorphisms tested with treatment response in RA patients receiving MTX. Until large prospective studies have been published, meta-analysis still remains the best tool for addressing such questions. Identification of predictive molecular variables, which could potentially inform treatment decisions ensuring that patients have access to the most effective first-line treatment for them, remains an important goal, but the data presented suggest that MTHFR polymorphisms are not predictive of MTX response in RA patients.
